Scarica l'app Stockscreener
82.14
1.41%
1.14
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Is Ionis Pharmaceuticals Inc a top pick in the sectorQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 12.94% Potential Upside Amidst Robust Pipeline - DirectorsTalk Interviews
Ionis, Otsuka win EU nod for hereditary angioedema therapy - MSN
Sovran Advisors LLC Lowers Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Guidance Update: Is Ionis Pharmaceuticals Inc being accumulated by smart moneyTrade Risk Report & Breakout Confirmation Alerts - baoquankhu1.vn
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly? - 富途牛牛
Ionis Pharmaceuticals, Inc. $IONS Position Reduced by Sector Gamma AS - MarketBeat
BLB&B Advisors LLC Has $7.76 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Teacher Retirement System of Texas Sells 194,328 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmac - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 3,977 Shares of Stock - MarketBeat
Ionis Pharmaceuticals EVP Devers sells $323,490 in stock By Investing.com - Investing.com Canada
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup - Chartmill
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Massachusetts Financial Services Co. MA Increases Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Retinitis Pigmentosa Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics - Barchart.com
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Ionis Pharmaceuticals (IONS) Gains EU Approval for Dawnzera - GuruFocus
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) - Business Wire
Dynasty Wealth Management LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 12,922 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $636,932.80 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $3,294,623.88 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP C Frank Bennett Sells 8,977 Shares - MarketBeat
Ionis Pharmaceuticals Executives Sell Shares - TradingView
Ionis Pharmaceuticals Executives Engage in Stock Transactions - TradingView
Big Picture: Is Ionis Pharmaceuticals Inc likely to announce a buyback2025 Pullback Review & Weekly Return Optimization Alerts - baoquankhu1.vn
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth - Seeking Alpha
United States Transthyretin Amyloid Cardiomyopathy Market - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Insider Trends: Does Ionis Pharmaceuticals Inc have consistent dividend growthJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Revenue Check: Can Ionis Pharmaceuticals Inc scale operations efficiently2025 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
JPM26: Tryngolza set to become first wholly owned Ionis blockbuster - Yahoo Finance
CEO Change: Can Ionis Pharmaceuticals Inc outperform in the next rally2025 Pullback Review & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Trend Recap: Why retail investors favor Ionis Pharmaceuticals Inc. stockJuly 2025 Setups & Long-Term Capital Growth Strategies - Bộ Nội Vụ
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthSector Rotation Strategies & Free Unmatched Market Performance - bollywoodhelpline.com
Lobbying Update: $60,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - marketscreener.com
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Will Ionis Pharmaceuticals Inc. stock outperform international peersBull Run & Weekly Watchlist for Hot Stocks - ulpravda.ru
Ionis Pharmaceuticals EVP Devers sells $3.7m in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Shannon Devers Sells 44,199 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 44,199 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
How resilient is Ionis Pharmaceuticals Inc. stock in market downturns2025 Price Action Summary & Weekly Stock Breakout Alerts - Улправда
Will Ionis Pharmaceuticals Inc. (ISI) stock benefit from infrastructure billEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Momentum Shift: Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Will Ionis Pharmaceuticals Inc. stock recover faster than peersEntry Point & Daily Risk Controlled Trade Plans - ulpravda.ru
Book value per share of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView — Track All Markets
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksGap Down & Technical Pattern Based Buy Signals - ulpravda.ru
Can Ionis Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Summary & Community Consensus Picks - Улправда
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - Nasdaq
Sentiment Review: Why Ionis Pharmaceuticals Inc. stock could see breakout soon - Улправда
Why Ionis Pharmaceuticals Inc. stock is a value investor pickTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Улправда
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 GoalsHas The Bull Case Changed? - Sahm
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):